Metformin reverses tamoxifen resistance through the lncRNA GAS5-medicated mTOR pathway in breast cancer

BACKGROUND: Metformin (Met) has antitumor effects on various cancers, but it is still unclear whether it exerts a reversible effect on endocrine resistance in breast cancer (BC) patients. In the present survey, metformin’s effects on tamoxifen-resistant MCF cells (The cell line was established at th...

Descripción completa

Detalles Bibliográficos
Autores principales: Jiang, Yiyan, Qian, Ting, Li, Suxia, Xie, Yuanyuan, Tao, Min
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9011257/
https://www.ncbi.nlm.nih.gov/pubmed/35434034
http://dx.doi.org/10.21037/atm-22-795

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9011257/
https://www.ncbi.nlm.nih.gov/pubmed/35434034
http://dx.doi.org/10.21037/atm-22-795

Ejemplares similares